Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
Revolutionary technology will further boost OneSource’s scientific services offerings
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
Thyrocare Technologies has reported total income of Rs. 160.53 crores during the period ended June 30, 2024
This transaction is the third acquisition by three different Japanese players in this segment
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission
PEKK is a high-performance polymer family used in aerospace and other demanding markets
Subscribe To Our Newsletter & Stay Updated
